Recombinant Human Brain protein 44 (BRP44)

What is BRP44/MPC2 and what is its role in mitochondrial function?

BRP44 (Brain protein 44), now officially known as Mitochondrial Pyruvate Carrier 2 (MPC2), is a 109 amino acid mitochondrial protein belonging to the UPF0041 family . It functions as an essential component of the mitochondrial pyruvate carrier complex, which mediates the uptake of pyruvate into mitochondria .

The MPC complex is crucial for cellular energy metabolism as it allows pyruvate generated from glycolysis to enter the mitochondria for oxidative phosphorylation. In neurons specifically, a constant supply of pyruvate to mitochondria is pivotal for function and survival. As noted in research: "maintenance of the neuronal membrane polarization resting potential under normal functional conditions is very much dependent on efficient ATP generation via oxidative phosphorylation" .

How do MPC1 (BRP44L) and MPC2 (BRP44) interact to form a functional carrier?

The mitochondrial pyruvate carrier consists of two paralogues:

• MPC1 (formerly known as BRP44L or Brain protein 44-like)

• MPC2 (formerly known as BRP44)

These two proteins were simultaneously identified in 2012 by the laboratories of Rutter and Martinou, which demonstrated that both components are required for proper mitochondrial pyruvate import . The functional evidence supporting their role included:

• Severe impairment of mitochondrial pyruvate import in yeast MPC1 mutants

• Expression of mammalian MPC1 and MPC2 in bacteria (Lactococcus lactis) conferred pyruvate uptake activity characteristic of eukaryotic UK-5099-sensitive mitochondrial pyruvate import

Research has shown that deletion of MPC1 in mouse models results in embryonic lethality, while point mutations in human MPC1 lead to impaired pyruvate oxidation with developmental abnormalities, neurological problems, and metabolic deficits .

What experimental approaches are used to study MPC inhibition?

Researchers employ several approaches to study MPC inhibition:

Chemical Inhibition:

• UK-5099: The most widely used specific MPC inhibitor that blocks pyruvate transport

• Thiazolidinediones (TZDs): Anti-diabetic drugs that were later discovered to inhibit MPC at clinically relevant concentrations

Genetic Approaches:

• Gene knockout studies in various model organisms

• Silencing of MPC expression in specific tissues or cell types

• MPC2 hypomorphic mouse lines harboring N-terminally truncated proteins

Metabolic Flux Analysis:

Researchers use stable isotope tracers (such as [1-13C1] glucose or [3-13C1] glucose) to measure changes in metabolic pathways when MPC is inhibited. This technique has revealed that:

• UK-5099 treatment significantly reduces incorporation of glucose-derived carbon into TCA cycle intermediates

• Cells adapt by increasing usage of alternative substrates such as leucine, β-hydroxybutyrate, and glutamine

What metabolic adaptations occur when MPC is inhibited?

When MPC is inhibited, cells undergo remarkable metabolic adaptations to maintain energy homeostasis:

• Substrate switching: Cells shift to alternative substrates for energy production:

  • Increased oxidation of leucine and β-hydroxybutyrate

  • Enhanced glutamine uptake and contribution to TCA cycle intermediates

• Maintenance of basal metabolic rate: Despite reduced pyruvate oxidation (by more than half), neurons treated with UK-5099 can maintain their basal metabolic rate without substantial elevation of cellular lactate levels

• Compensation for loss of pyruvate-based anaplerosis: Cells increase glutamate oxidation to compensate for reduced pyruvate entry into the TCA cycle

• Resistance to cell death: Unlike respiratory chain inhibitors (such as antimycin A) which cause rapid death, neurons maintained with MPC inhibitor UK-5099 remain viable for 3 days or more despite having significantly reduced pyruvate oxidizing capacity

These adaptations demonstrate the remarkable metabolic flexibility of cells when facing MPC inhibition.

How does experimental design affect studies of MPC function?

When designing experiments to study MPC function, researchers should consider several critical factors:

How does MPC inhibition confer neuroprotection in disease models?

One of the most intriguing discoveries about MPC inhibition is its neuroprotective effects in certain neurological conditions:

Parkinson's Disease Models:

MPC inhibition has been shown to be beneficial in experimental models of neurotoxicity, particularly in Parkinson's disease contexts .

Excitotoxic Neuronal Death:

In a key study by Divakaruni and colleagues, MPC inhibition protected against excitotoxic neuronal death:

• Rat cortical neurons treated with UK-5099 remained viable for 3+ days despite reduced pyruvate oxidation

• Neurons readily switched to alternative substrates (leucine, β-hydroxybutyrate)

• These non-glucose substrates reversed alterations in glycolytic rate and total ATP production

• MPC inhibition led to increased glutamine uptake and carbon fluxes from glutamine to TCA cycle intermediates

The mechanism appears to involve metabolic rewiring that allows neurons to maintain energy homeostasis while reducing reactive oxygen species (ROS) production. This is particularly interesting since increased oxidative metabolism is often associated with increased ROS generation, yet MPC re-expression in certain cancer cell lines led to decreased ROS levels .

What are the technical challenges in producing and working with recombinant BRP44/MPC2?

Working with recombinant mitochondrial membrane proteins presents several technical challenges:

Expression Systems:

• Cell-free expression systems: Can be used for producing transmembrane proteins like BRP44

• E. coli: While commonly used for recombinant protein production, membrane proteins often require specialized strains and conditions

Protein Validation:

Recombinant BRP44/MPC2 can be validated through:

• Western blotting with specific antibodies

• Functional assays measuring pyruvate transport activity

• Blocking experiments using protein fragments as controls

Storage and Handling:

• Recombinant proteins in solution are temperature sensitive and must be stored at -80°C

• Repeated freeze/thaw cycles should be avoided

• Recombinant proteins should be kept on ice when not in storage

How can researchers distinguish between direct effects of MPC inhibition versus secondary metabolic adaptations?

This represents one of the most challenging aspects of MPC research. Strategies include:

• Time-course experiments: Measuring metabolic parameters at multiple time points after MPC inhibition can help distinguish immediate direct effects from later adaptive responses.

• Metabolic flux analysis: Using isotope-labeled substrates can track changes in specific metabolic pathways:

  • [1-13C1] glucose tracing for glycolytic flux

  • [3-13C1] glucose for anaplerotic contributions to the TCA cycle

• Concurrent use of other metabolic inhibitors: Blocking alternative pathways while inhibiting MPC can reveal compensatory mechanisms.

• Genetic versus pharmacological approaches: Comparing acute inhibition (UK-5099) with genetic knockdown can help distinguish between immediate effects and adaptations.

• Multi-omics approaches: Combining metabolomics, proteomics, and transcriptomics can provide a comprehensive view of cellular responses to MPC inhibition.

What is the relationship between BRP44/MPC2 and disease states?

BRP44/MPC2 has been implicated in several disease contexts:

Cancer:

• Several decades-old observations suggested that MPC might be inactivated in cancer cell lines and tumors

• The decrease in pyruvate oxidation is associated with the Warburg effect in cancer cells

• Re-expression of MPC in certain cancer cell lines restored mitochondrial pyruvate uptake, increased oxygen consumption, and elevated 14CO2 production from [1-14C]-pyruvate

Neurological Disorders:

• Point mutations in human MPC1 result in developmental abnormalities and neurological problems

• MPC inhibition has shown protective effects in Parkinson's disease models and against excitotoxic neuronal death

Metabolic Disorders:

• MPC plays a prominent role in glucose-stimulated insulin secretion

• Pharmacological inhibition or silencing of MPC in pancreatic β-cells blocks glucose-stimulated insulin secretion

• MPC2 hypomorphic mice exhibit glucose intolerance attributed to impaired glucose-stimulated pancreatic insulin release

What are the current frontiers and unresolved questions in MPC research?

Several important questions remain in MPC research: